Tesla
TSLA
Netflix
NFLX
Disney
DIS
4
Cisco
CSCO
5
Meta Platforms
META
US Stock MarketDetailed Quotes
THAR Tharimmune
- 1.480
- +0.120+8.82%
Close Apr 29 16:00 ET
- 1.580
- +0.100+6.74%
Pre 08:48 ET
3.12MMarket Cap-0.16P/E (TTM)
1.500High1.280Low291.74KVolume1.400Open1.360Pre Close413.02KTurnover14.04%Turnover RatioLossP/E (Static)2.11MShares6.44952wk High2.39P/B3.07MFloat Cap0.95252wk Low--Dividend TTM2.08MShs Float1590.000Historical High--Div YieldTTM16.18%Amplitude0.952Historical Low1.415Avg Price1Lot Size
Tharimmune Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If ...
20
11
$Tharimmune (THAR.US)$ Tharimmune Says FDA Confirmed No Additional Trials Appear To Be Necessary Prior To A 505(b)(2) New Drug Application Submission
Benzinga· 4 mins ago
Benzinga· 4 mins ago
$Tharimmune (THAR.US)$
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Monday, 28th April at 8:01 am
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (NASDAQ: THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced positive feedback from the U.S. Food and Drug A...
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Monday, 28th April at 8:01 am
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (NASDAQ: THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced positive feedback from the U.S. Food and Drug A...
3
$Tharimmune (THAR.US)$
Tharimmune's preclinical data announcement marks a meaningful advancement for their multispecific antibody platform. The company's EpiClick technology appears to be delivering on its promise of accessing novel epitopes with two key candidates now showing promising in vitro potency.
The PD-1/VEGF bispecific (HS1940) represents a rational combination of immuno-oncology and anti-angiogenesis approaches. With EC50 values of 2.1nM for PD-1 and 2.56nM for VEG...
Tharimmune's preclinical data announcement marks a meaningful advancement for their multispecific antibody platform. The company's EpiClick technology appears to be delivering on its promise of accessing novel epitopes with two key candidates now showing promising in vitro potency.
The PD-1/VEGF bispecific (HS1940) represents a rational combination of immuno-oncology and anti-angiogenesis approaches. With EC50 values of 2.1nM for PD-1 and 2.56nM for VEG...
$Tharimmune (THAR.US)$
This preclinical data release demonstrates Tharimmune's progress in leveraging their EpiClick platform to produce differentiated oncology assets. Both candidates target well-validated oncology pathways but with potentially novel approaches to epitope binding.
The PD-1/VEGF bispecific space has become increasingly competitive, with Summit Therapeutics' ivonescimab leading development in the US market. Tharimmune's HS1940 attempts differentiation ...
This preclinical data release demonstrates Tharimmune's progress in leveraging their EpiClick platform to produce differentiated oncology assets. Both candidates target well-validated oncology pathways but with potentially novel approaches to epitope binding.
The PD-1/VEGF bispecific space has become increasingly competitive, with Summit Therapeutics' ivonescimab leading development in the US market. Tharimmune's HS1940 attempts differentiation ...
$Tharimmune (THAR.US)$
Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition
Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition
$Tharimmune (THAR.US)$
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Monday, 7th April at 8:00 am
BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced preclinical data from its expanded pipeline with HS1940, a dual-target multispe...
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Monday, 7th April at 8:00 am
BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced preclinical data from its expanded pipeline with HS1940, a dual-target multispe...
1
$Tharimmune (THAR.US)$
FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed
FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed
$Tharimmune (THAR.US)$
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Monday, 31st March at 8:00 am
-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway
-Company leveraging existing human pharmacokinetic data with TH104
-Advancing CMC plan to meet requirements of a New Drug Application
BRIDGEWATER, NJ / ACCESS Newswire / March 31, 2025 / Tharimmune, Inc. (...
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Monday, 31st March at 8:00 am
-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway
-Company leveraging existing human pharmacokinetic data with TH104
-Advancing CMC plan to meet requirements of a New Drug Application
BRIDGEWATER, NJ / ACCESS Newswire / March 31, 2025 / Tharimmune, Inc. (...
1
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
32
8
1
No comment yet
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
Josam456 : any opinion on $Damon (DMN.US)$ ? or is it just a wait and see?
Kobashi : I might go crazy on Jaguar Health because of you man lol
Jaguar8 OP Josam456 : No after hours trading but chart is good. May continue tomorrow. Ill see if i will add it latet
かつやっチョッ : Good morning
MoonGazer かつやっチョッ :
View more comments...